Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer

Acta Oncologica

Volumn 39, Issue 2, 2000, Pages 225-229

  Goh, Boon C ^a   Lehnert, Manfred ^a   Lim, Hong L ^a   Ng, Alan W K ^b   Chan, Choong C ^b   Kong, Hwai L ^a   Lee, Soo C ^a   Wee, Joseph ^c   Chua, E T ^c   Wong, John E L ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

ADULT; AGED; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034068310     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600430824     Document Type: Article

References (25)

1. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55.
2. Bissery MC. Preclinical pharmacology of docetaxel, Eur J Cancer 1995; 31A (Suppl 4): S1-6.
3. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of taxotere 5 day schedule. J Natl Cancer Inst 1992; 84: 1781-8.
4. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42.
5. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993; 11: 950-8.
6. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523-7.
7. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384-7.
8. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
9. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
10. Rigas, JR. Docetaxel in stage III and IV non-small cell lung cancer. Eur J Cancer 1995; 31A (Suppl 4): S18-20.
11. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996; 4: 1649-55.
12. Dillman R, Seagren S, Propert K, et al. A randomised trial of induction chemotherapy plus high dose radiation vs radiation alone in Stage III non-small cancer. N Engl J Med 1990; 323: 940-5.
13. Sause WT, Scott C, Taylor S, et al. Radiation Therapy and Oncology Group (RTOG) 8808 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
14. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89 (Suppl): 225.
15. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
16. Gehan A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-53.
17. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7: 1087-92.
18. Shepherd FA, Burkes R, Cormier Y, et al. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer: usefulness of mathematical modeling to determine the maximum-tolerable dose. J Clin Oncol 1996; 14: 1656-62.
19. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-94.
20. Depierre A, Lomaine E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 124: 115-9.
21. 2 dose of docetaxel with prednisolone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-72.
22. Freyer G, Ligneau B, Tranchand B, Ardiet C, Serre-Debeauvais F, Trillet-Lenoir V. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997; 23: 153-69.
23. Baille P, Bruno R, Schellens JHM, et al. Optimal sampling strategy for Bayesian estimation of docetaxel (taxotere) clearance. Clin Cancer Res 1997; 3: 1535-8.
24. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96.
25. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704.